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EDITORIAL

Special Issue on Cell Therapy
Gustavo Moviglia
(Guest Editor)
Wake Forest Institute for Regenerative Medicine of Wake Forest University, North Caroline, USA

The current issue of the Journal of Neurores‐
toratology constitutes the most complete and
updated compendium of the use of olfactory
ensheathing cells (OEC) in clinic use for
different traumatic and vascular pathologies of
the central nervous system.
The identification of OECs as neural stem cells
was carried out by Graziadei PP, first in birds [1]
and then in mammals, between 1979 and 1980. In
the 1990s, in parallel, Professors Ramon Cueto [2]
and Raisman [3], both founders of the IANR,
studied its therapeutic potential for injuries of
the central nervous system in preclinical trials.
These findings were also corroborated by other
laboratories. Between 2001 and 2003, Professors
Huang [4] and Rabinovich [5] transplanted
OECs from abortion fetal olfactory bulb in
patients with chronic complete spinal cord
injury (SCI) and showed improvement of
neurological functions. Simultaneously Professor
Carlo Lima, from Portugal, treated 7 patients
with chronic spinal cord injury with autologous
olfactory mucosa. In 2006 he published the
clinical follow‐up of these first 7 patients treated,
demonstrating that the treatment indicated to be
safe and effective to treat severe and chronic
spinal cord injuries [6].
In this issue, Professor Xijing He’s team
presents an analytical work, organized by
Zhijian Cheng and 8 other co‐authors, of what
happened with 13 patients treated between 2005

and 2007. In these patients, it was used by direct
injection of fetal OECs. 16 years later, none of
those treated presented any abnormal develop‐
ment (benign or malignant tumors) or secondary
autoimmune reactions, but showed clinical
improvements. For this reason, the patients with
the surgical method of OEC implants is safe and
seems to be effective in the treatment of patients
with chronic and complete lesions of the spinal
cord, which allows the authors to conclude that
this is a valid possibility to treat patients via
surgery with fetal OEC.
The team of Professor Zuncheng Zheng, in a
study carried out by Naifeng Kuang and 9
collaborators, summarizes the clinical experience
of 39 patients with spinal cord injury who
between 2006 and 2007 also received fetal OEC
by surgical implant in the area of injury. The
results of this clinical trial conducted
simultaneously with the aforementioned one
corroborate the findings of Professor He’s team
corroborate the safety and efficacy of fetal OEC.
The excellent work done by Professor Huang
Hongyun’s team using the intranasal rout of
administration for fetal OEC in patiens with
vascular dementia shows the safety and efficacy
of this therapy. This paper is supported for the
review paper presented by Shaomin Li and his
team on the effects of OEC on vascular lesions of
the brain.
Finally, Professor Alok Sharma using bone
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marrow mononuclear cells summarizes his
valuable experience of more than a decade
treating 216 patients with amyotrophic lateral
sclerosis in different clinical conditions. The
doubling of the expectation of life of the patients
treated with respect to the patients of the control
group as well as the identification of the patients
who can benefit the most from this therapy
become a solid endorsement and scientific
foundation for those of us who work on this
pathology.
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